Skip to content
OpenCapital
Get started

Kyverna Therapeutics, Inc. KYTX Finance Lease, Principal Payments

Finance Lease, Principal Payments at other companies

Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
——

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0×0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeasePrincipalPayments.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s finance lease, principal payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s finance lease, principal payments?
Kyverna Therapeutics, Inc. (KYTX) reported finance lease, principal payments of $86K in Q1 2026.
How has Kyverna Therapeutics, Inc.'s finance lease, principal payments changed year-over-year?
Kyverna Therapeutics, Inc.'s finance lease, principal payments decreased by 74.8% year-over-year, from $341K to $86K.
What is the long-term trend for Kyverna Therapeutics, Inc.'s finance lease, principal payments?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s finance lease, principal payments has grown at a 1.8% compound annual growth rate (CAGR), from $780K to $808K.